Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protagonist Therapeutics Inc PTGX

Healthcare Biotechnology
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its... see more

Recent & Breaking News (NDAQ:PTGX)

Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications

Accesswire October 9, 2023

Protagonist Therapeutics Reports Granting of Inducement Award

Accesswire October 3, 2023

Protagonist Therapeutics to Present at Upcoming Investor Conferences

Accesswire September 5, 2023

Protagonist Therapeutics Reports Granting of Inducement Award

Accesswire August 16, 2023

Protagonist Receives $34 Million from Warrant Exercises

Accesswire August 9, 2023

Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Accesswire August 3, 2023

Protagonist Therapeutics Reports Granting of Inducement Award

Accesswire July 18, 2023

Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Rusfertide in PV

Accesswire June 9, 2023

Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress

Accesswire June 6, 2023

Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

Accesswire June 1, 2023

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

PR Newswire May 12, 2023

Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference

PR Newswire May 11, 2023

Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association

PR Newswire May 11, 2023

Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire May 4, 2023

Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock

Accesswire April 4, 2023

Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Accesswire April 4, 2023

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Accesswire March 15, 2023

Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera

Accesswire March 15, 2023

Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis

PR Newswire March 7, 2023

Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

PR Newswire December 21, 2022